SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results

Charles C. Wykoff; David M. Brown; Eric Chen; James C. Major; Daniel E. Croft; Angeline Mariani; Tien P. Wong

doi:10.3928/23258160-20130313-04

SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results

Charles C. Wykoff, David M. Brown, Eric Chen, James C. Major, Daniel E. Croft, Angeline Mariani, Tien P. Wong

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Objectives: To assess durability of visual and anatomic gains with 2.0 mg ranibizumab in recalcitrant neovascular age-related macular degeneration (AMD). Methods: Phase I-II trial of 88 patients with recalcitrant neovascular AMD treated as needed every 4 (cohort A) or 6 weeks (cohort B) following three monthly doses. ETDRS refraction and spectral-domain OCT-guided as-needed re-treatments. Results: Seventy-nine patients completed the 12-month endpoint and were given 11.6 (cohort A) and 8.6 (cohort B) mean treatments. Mean best corrected visual acuity gains of 4.1 letters following three monthly doses were sustained for 12 months for both cohorts. Anatomic improvements were sustained for 12 months for cohort A, but not for cohort B; cohort B demonstrated a gradual increase in mean central retinal thickness (P = .03). Conclusion: Visual and anatomic gains achieved with 2.0 mg ranibizumab in recalcitrant neovascular AMD were sustained for 1 year with monthly treatment. In comparison, anatomic gains were diminished with less than monthly treatment.

Original language	English (US)
Pages (from-to)	121-126
Number of pages	6
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	44
Issue number	2
DOIs	https://doi.org/10.3928/23258160-20130313-04
State	Published - Mar 2013

ASJC Scopus subject areas

Surgery
Ophthalmology

Access to Document

10.3928/23258160-20130313-04

Fingerprint Dive into the research topics of 'SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results'. Together they form a unique fingerprint.

Cite this

SAVE (super-dose anti-VEGF) trial : 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. / Wykoff, Charles C.; Brown, David M.; Chen, Eric ; Major, James C.; Croft, Daniel E.; Mariani, Angeline; Wong, Tien P.

In: Ophthalmic Surgery Lasers and Imaging Retina, Vol. 44, No. 2, 03.2013, p. 121-126.

Research output: Contribution to journal › Article › peer-review

@article{89ff188874c54ebf8755d1444574d5c9,

title = "SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results",

abstract = "Objectives: To assess durability of visual and anatomic gains with 2.0 mg ranibizumab in recalcitrant neovascular age-related macular degeneration (AMD). Methods: Phase I-II trial of 88 patients with recalcitrant neovascular AMD treated as needed every 4 (cohort A) or 6 weeks (cohort B) following three monthly doses. ETDRS refraction and spectral-domain OCT-guided as-needed re-treatments. Results: Seventy-nine patients completed the 12-month endpoint and were given 11.6 (cohort A) and 8.6 (cohort B) mean treatments. Mean best corrected visual acuity gains of 4.1 letters following three monthly doses were sustained for 12 months for both cohorts. Anatomic improvements were sustained for 12 months for cohort A, but not for cohort B; cohort B demonstrated a gradual increase in mean central retinal thickness (P = .03). Conclusion: Visual and anatomic gains achieved with 2.0 mg ranibizumab in recalcitrant neovascular AMD were sustained for 1 year with monthly treatment. In comparison, anatomic gains were diminished with less than monthly treatment.",

author = "Wykoff, {Charles C.} and Brown, {David M.} and Eric Chen and Major, {James C.} and Croft, {Daniel E.} and Angeline Mariani and Wong, {Tien P.}",

year = "2013",

month = mar,

doi = "10.3928/23258160-20130313-04",

language = "English (US)",

volume = "44",

pages = "121--126",

journal = "Ophthalmic surgery, lasers & imaging retina",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "2",

}

TY - JOUR

T1 - SAVE (super-dose anti-VEGF) trial

T2 - 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results

AU - Wykoff, Charles C.

AU - Brown, David M.

AU - Chen, Eric

AU - Major, James C.

AU - Croft, Daniel E.

AU - Mariani, Angeline

AU - Wong, Tien P.

PY - 2013/3

Y1 - 2013/3

N2 - Objectives: To assess durability of visual and anatomic gains with 2.0 mg ranibizumab in recalcitrant neovascular age-related macular degeneration (AMD). Methods: Phase I-II trial of 88 patients with recalcitrant neovascular AMD treated as needed every 4 (cohort A) or 6 weeks (cohort B) following three monthly doses. ETDRS refraction and spectral-domain OCT-guided as-needed re-treatments. Results: Seventy-nine patients completed the 12-month endpoint and were given 11.6 (cohort A) and 8.6 (cohort B) mean treatments. Mean best corrected visual acuity gains of 4.1 letters following three monthly doses were sustained for 12 months for both cohorts. Anatomic improvements were sustained for 12 months for cohort A, but not for cohort B; cohort B demonstrated a gradual increase in mean central retinal thickness (P = .03). Conclusion: Visual and anatomic gains achieved with 2.0 mg ranibizumab in recalcitrant neovascular AMD were sustained for 1 year with monthly treatment. In comparison, anatomic gains were diminished with less than monthly treatment.

AB - Objectives: To assess durability of visual and anatomic gains with 2.0 mg ranibizumab in recalcitrant neovascular age-related macular degeneration (AMD). Methods: Phase I-II trial of 88 patients with recalcitrant neovascular AMD treated as needed every 4 (cohort A) or 6 weeks (cohort B) following three monthly doses. ETDRS refraction and spectral-domain OCT-guided as-needed re-treatments. Results: Seventy-nine patients completed the 12-month endpoint and were given 11.6 (cohort A) and 8.6 (cohort B) mean treatments. Mean best corrected visual acuity gains of 4.1 letters following three monthly doses were sustained for 12 months for both cohorts. Anatomic improvements were sustained for 12 months for cohort A, but not for cohort B; cohort B demonstrated a gradual increase in mean central retinal thickness (P = .03). Conclusion: Visual and anatomic gains achieved with 2.0 mg ranibizumab in recalcitrant neovascular AMD were sustained for 1 year with monthly treatment. In comparison, anatomic gains were diminished with less than monthly treatment.

UR - http://www.scopus.com/inward/record.url?scp=84875984205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875984205&partnerID=8YFLogxK

U2 - 10.3928/23258160-20130313-04

DO - 10.3928/23258160-20130313-04

M3 - Article

C2 - 23510037

AN - SCOPUS:84875984205

VL - 44

SP - 121

EP - 126

JO - Ophthalmic surgery, lasers & imaging retina

JF - Ophthalmic surgery, lasers & imaging retina

SN - 2325-8160

IS - 2

ER -

SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this